

2011 Annual Report

Partnerships for Change



In the third year since its incorporation, the Reagan-Udall Foundation for the Food and Drug Administration continues advancing the FDA's mission to modernize medical, veterinary, food, food ingredient and cosmetic product development; accelerate innovation; and enhance product safety pursuant to the Federal Food, Drug, and Cosmetic Act.

Accelerating Tuberculosis Drug Regimes. In the previous year, the Foundation joined forces with the Bill and Melinda Gates Foundation on the *Critical Path for Tuberculosis Drug Regimens (CPTDR)*. This important project helps accelerate the development and impact of new and improved drug regimens to treat tuberculosis. A consortium of stakeholders, including the Gates Foundation, Critical Path Institute and the TB Alliance, CPTDR's endgame is to overcome obstacles to new, timely TB drugs.

Confronting Cancer Treatment Toxicity. With Susan G. Komen for the Cure support, the Foundation began a pilot project to better understand treatment toxicity in specific cancer populations. The *Systems Toxicology Project* kicked off in July when the Foundation convened stakeholders to discuss a systems approach to address toxicology. Subsequently, the Foundation began planning a project expansion to include cancer treatments outside of those for breast cancer only.

Building a System for Greater Private-Sector Use of FDA Data. In 2011, the Foundation began building the infrastructure to take over and build upon the Observational Medical Outcomes Partnership, a national electronic system that shares FDA's post-market data to aid researchers in monitoring FDA-regulated medical products' safety. The Foundation's new program, *Innovation in Medical Evidence Development and Surveillance (IMEDS)*, will help FDA improve broader public health and real-world medical evidence generation. Throughout the year, the Foundation secured needed resources, built the program's infrastructure and created the guiding rules to provide unprecedented access to private-sector entities such as industry, academic institutions and nonprofit organizations.

2011 BOARD of DIRECTORS

Chair	<i>Mark McClellan, MD, PhD, 18th FDA Commissioner</i>
Vice Chair	<i>Ellen Sigal, PhD, Chair and Founder, Friends of Cancer Research</i>
Secretary	<i>Kay Holcombe, Senior Vice President for Science Policy, Biotechnology Innovation Organization</i>
Treasurer	<i>Georges Benjamin, MD, Executive Director, American Public Health Association</i>
Directors	<i>Pamela G. Bailey, President and CEO, Grocery Manufacturers Association</i>
	<i>Donald M. Casey, MBA, CEO, Gary and Mary West Wireless Health Institute</i>
	<i>William W. Chin, MD, Executive Dean for Research, Harvard Medical School</i>
	<i>Helen Darling, President, National Business Group on Health</i>
	<i>Sally J. Greenberg, JD, Executive Director, National Consumers League</i>
	<i>Sharon Levine, MD, Associate Executive Director, Permanente Medical Group</i>
	<i>Garry Neil, MD, Corporate VP of Science and Technology, Johnson & Johnson</i>
	<i>Phillip Sharp, PhD, Professor of Biology and Member, Koch Institute</i>
	<i>Tadataka Yamada, MD, Executive Director of Global Health, Bill and Melinda Gates Foundation</i>
	<i>Diana Zuckerman, PhD, President, National Center for Health Research</i>
Ex officio:	<i>Francis S. Collins, MD, PhD, Director, National Institutes of Health</i>
Ex officio:	<i>Margaret Hamburg, MD, 21st FDA Commissioner</i>
Executive Director	<i>Jane Reese-Coulbourne</i>

As a 501(c)3, the Foundation makes its financials publicly available. Please view its 2011 [IRS Form 990](#) and [Audit and Financial Report](#).

Reagan-Udall Foundation for the Food and Drug Administration

1025 Connecticut Avenue NW STE 1000

Washington, DC 20036